Archimed Acquires PET Radiopharmaceuticals Company IRAB

Deal Summary

Archimed announced the acquisition of IRAB, a Barcelona‑based developer of PET radiopharmaceuticals used for clinical diagnosis, trials, and biomedical research. The deal expands Archimed’s molecular imaging portfolio and strengthens its presence in the radiopharmaceutical market. Financial terms were not disclosed.